Disclosures for "Results from the ADAPT JR Study Investigating Intravenous Efgartigimod in Juvenile Generalized Myasthenia Gravis"
-
Dr. Schwaede has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Schwaede has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen .
-
Dr. Kuntz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Kuntz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenyx. Dr. Kuntz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Audentes Therapeutics. Dr. Kuntz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Kuntz has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Kuntz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Catalyst. Dr. Kuntz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Scholar Rock. The institution of Dr. Kuntz has received research support from Argenx. The institution of Dr. Kuntz has received research support from Astellas. The institution of Dr. Kuntz has received research support from Biogen. The institution of Dr. Kuntz has received research support from Catalyst. The institution of Dr. Kuntz has received research support from Genentech. The institution of Dr. Kuntz has received research support from Scholar Rock. The institution of Dr. Kuntz has received research support from Regenx-Bio. The institution of Dr. Kuntz has received research support from Solid Biosciences. The institution of Dr. Kuntz has received research support from AMO. The institution of Dr. Kuntz has received research support from Novartis. The institution of Dr. Kuntz has received research support from BioHaven. Dr. Kuntz has received personal compensation in the range of $50,000-$99,999 for serving as a Sarepta Express post gene therapy advisor with Sarepta.
-
Dr. Ramdas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Ramdas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for pfizer. Dr. Ramdas has received personal compensation in the range of $0-$499 for serving as a Consultant for Italfarmaco. Dr. Ramdas has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Ramdas has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. The institution of Dr. Ramdas has received research support from Myaware . The institution of Dr. Ramdas has received research support from Norman Collison Foundation. .
-
Dr. Anna has received personal compensation for serving as an employee of argenx BV.
-
Dr. Giacobbe has received personal compensation for serving as an employee of argenx. Dr. Giacobbe has stock in argenx.
-
Dr. Menezes has received personal compensation for serving as an employee of argenx.
-
Mrs. Lan has received personal compensation for serving as an employee of argenx.
-
The institution of Mr. Noukens has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Argenx.
-
The institution of Mrs. van Bragt has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for argenx. Mrs. van Bragt has stock in argenx.
-
Dr. Niks has nothing to disclose.
-
Prof. Kostera-Pruszczyk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Prof. Kostera-Pruszczyk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Prof. Kostera-Pruszczyk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Prof. Kostera-Pruszczyk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Prof. Kostera-Pruszczyk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Prof. Kostera-Pruszczyk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Prof. Kostera-Pruszczyk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Astra Zeneka. Prof. Kostera-Pruszczyk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx.